ferric hydroxide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4539 1309-33-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ferric hydroxide
  • ferric trihydroxide
additional RNs for iron hydroxide oxide: 11115-92-7, 20344-49-4; RN for unspecified iron hydroxide: 11113-66-9
  • Molecular weight: 106.87
  • Formula: FeH3O3
  • CLOGP: -1.75
  • LIPINSKI: None
  • HAC: 3
  • HDO: 3
  • TPSA: 60.69
  • ALOGS:
  • ROTB: 0

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IRAK1,ITK,JAK1,JAK2,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK7,MAPK9,MARK4,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 63
kinase-selectivity-class ACVR2B,ACVRL1,AXL,BMX,BRAF,CDK4,CDK9,EPHB4,GRK2,IRAK3,MAP2K6,MAP3K14,MAPK7,PIK3CD,PIK3CG,PRKDC,STK33,SYK,TEK,TGFBR1,ZAP70 21
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Arteriovenous fistula site complication 320.63 125.59 34 162 475 90627776
Hospitalisation 158.33 125.59 39 157 128061 90500190

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Arteriovenous fistula site complication 446.90 83.29 55 499 430 42620351
Hospitalisation 307.90 83.29 86 468 74244 42546537
Angina pectoris 111.83 83.29 33 521 32863 42587918

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Arteriovenous fistula site complication 752.88 81.13 89 701 941 110587568
Hospitalisation 477.69 81.13 123 667 142370 110446139
Angina pectoris 173.86 81.13 47 743 62248 110526261

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B03AB04 BLOOD AND BLOOD FORMING ORGANS
ANTIANEMIC PREPARATIONS
IRON PREPARATIONS
Iron trivalent, oral preparations
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:75835 anti-anaemic agent

Related Drugs by ATC class:

B03AB Iron trivalent, oral preparations 4 drugs
chondroitin sulfate-iron complexferric maltolsodium feredetatesucroferric oxyhydroxide

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
CHEBI:135985 CHEBI
CHEMBL4802224 ChEMBL_ID
CHEMBL3707285 ChEMBL_ID
C021024 MESH_SUPPLEMENTAL_RECORD_UI
DB13423 DRUGBANK_ID
2UA751211N UNII
1428835 RXNORM
007463 NDDF
C0060236 UMLSCUI
73964 PUBCHEM_CID

Pharmaceutical products:

None